Clinical Trial Update: Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity

View source ↗

Summary

A registry study observing EndoBarrier treatment outcomes in subjects with type 2 diabetes and obesity has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• EndoBarrier (duodenal-jejunal bypass liner)

Snippet

Sponsor: Morphic Medical Inc. | Conditions: Type 2 Diabetes, Obesity | Status: TERMINATED